{"id":"W4415280517","doi":"10.1158/2767-9764.crc-25-0305","title":"The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)","year":2025,"lang":"en","type":"article","venue":"Cancer Research Communications","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; AstraZeneca; Bristol-Myers Squibb; Eli Lilly and Company; Pharmaceuticals Bayer; Ipsen; Astellas Pharma; Eisai; Gilead Sciences; Pfizer; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Cisplatin; Solid tumor; Clinical trial; Cancer; Phases of clinical research; Ataxia-telangiectasia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001282527,0.0007635432,0.001003199,0.0003104453,0.000340743,0.0005726453,0.0008345342,0.0006141177,0.002276389],"category_scores_gemma":[0.0005615216,0.0003469844,0.0005640273,0.0004319217,0.0006005137,0.0003899366,0.0002946741,0.002003731,0.0004047766],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001180026,"about_ca_system_score_gemma":0.001784094,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003028975,"about_ca_topic_score_gemma":0.01037942,"domain_scores_codex":[0.9997001,0.0001563432,0.00001736658,0.00005193021,0.00003677381,0.00003741652],"domain_scores_gemma":[0.9996052,0.00005855498,0.0001031555,0.00003018366,0.00003097973,0.0001718742],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4266027,0.05635239,0.03398947,0.002443792,0.003544171,0.0004519981,0.0004524378,0.01054833,0.07057407,0.0006367737,0.02580629,0.3685975],"study_design_scores_gemma":[0.5532956,0.3790205,0.04110887,0.0001566332,0.001708315,0.0006386556,0.00007922991,0.003867909,0.006712373,0.0001512075,0.01321297,0.00004773186],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9901448,0.004321536,0.0004305985,0.0006707175,0.00007448161,0.001037298,0.0005698297,0.0001357161,0.002614899],"genre_scores_gemma":[0.9886651,0.00337059,0.001981654,0.000783908,0.000147389,0.0009358612,0.001839569,0.00002543871,0.002250546],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003028975,"threshold_uncertainty_score":0.00856173,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02733874823644689,"score_gpt":0.3955000211396913,"score_spread":0.3681612729032444,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}